Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 27, 2015 12:22 PM ET

Healthcare Providers and Services

Company Overview of NicOx Inc.

Company Overview

NicOx Inc. distributes nitric oxide (NO)-donating drug-candidates for inflammatory, cardio metabolic, and ophthalmological diseases. The company was founded in 2000 and is based in Warren Township, New Jersey. As of November 17, 2014, NicOx Inc. operates as a subsidiary of Valeant Pharmaceuticals International, Inc.

15 Independence Boulevard

4th Floor

Suite 430

Warren Township, NJ 07059

United States

Founded in 2000





Key Executives for NicOx Inc.

Chairman of Nicox and Chief Executive Officer of Nicox
Age: 61
Executive Vice President and General Manager
Director of Commercial Development & Strategic Alliances
Executive Vice President of Corporate Development -Nicox S.A.
National Director of Sales
Compensation as of Fiscal Year 2015.

NicOx Inc. Key Developments

Nicox Focuses US Operations on National Launches of Sjo(TM) and Retnagene(TM) and Restructures RPS(R) Licensing Agreement

Nicox S.A. announced that Nicox's subsidiary, Nicox Inc, will focus its US sales force on supporting the national roll-out of Sjö(TM), an advanced diagnostic panel for the early detection of Sjögren's syndrome in patients with dry eye, and on promoting the RetnaGene(TM) portfolio including RetnaGene(TM) AMD and RetnaGene(TM) LR, specialized genetic tests which assess an individual's risk for advanced age-related macular degeneration (AMD). Nicox and Rapid Pathogen Screening (RPS(R)) have therefore agreed to restructure the terms of their partnership in North America. Effective August 1st, 2014, RPS(R) will resume responsibility for marketing AdenoPlus(R), a point-of-care diagnostic test that aids in the differential diagnosis of acute conjunctivitis, to eye care professionals in North America, as well as two other diagnostic products currently in development. RPS(R) will pay a royalty on sales to Nicox. Nicox will continue to have rights to commercialize AdenoPlus(R) and the previously licensed development products in all markets outside of North America. Because of the dedicated focus on successfully commercializing Sjö(TM) and RetnaGene(TM), Nicox and RPS(R) have agreed to restructure the North American portion of the licensing agreement relating to AdenoPlus(R) and two products in development, RPS-AP, a panel test for the diagnosis of adenoviral and allergic conjunctivitis and RPS-OH, a test for the diagnosis of ocular herpes. RPS(R) currently markets the AdenoPlus(R) test to primary and urgent care professionals in the US. Effective August 1st, 2014, RPS(R) will assume responsibility for marketing to eye care professionals in the US and all medical practitioners in Canada. RPS(R) will pay Nicox single-digit royalties on sales. Nicox will no longer market these products in the US and Canada but retains a co-promotion option in these markets, with complementary therapeutics that Nicox may obtain in the future. No additional rights to other RPS(R) products have been transferred. Nicox will continue to exclusively commercialize the RPS(R) products outside the US and Canada, and RPS(R) and Nicox have extended their manufacturing agreement to ensure long-term product supply at favorable prices. Nicox anticipates launching the tests in development, to be marketed by Nicox as AAT and OHT, in Europe in 2015.

Nicox Inc. and Sequenom Announce the Launch of Expanded Access to ReRetnaGene(TM) Test Portfolio in the U.S

Nicox S.A. and Sequenom Inc. announced that Nicox's subsidiary, Nicox Inc. is launching expanded access to Sequenom Laboratories' RetnaGene(TM) portfolio of laboratory-developed genetic tests in the United States (U.S.). The RetnaGene portfolio includes RetnaGene AMD and RetnaGene LR, specialized genetic tests, which assess an individual's risk for advanced age-related macular degeneration (AMD). AMD is the most common cause of visual impairment and the leading cause of blindness in the elderly population in the developed world. The RetnaGene portfolio includes two laboratory-developed genetic tests performed exclusively by Sequenom Laboratories that evaluate an individual's risk of advanced AMD. The RetnaGene AMD test assesses the risk for wet AMD (also called choroidal neovascularization, CNV) within two, five and ten years in patients aged 55 and older with early or intermediate dry AMD. The RetnaGene(TM) LR test assesses the lifetime risk of advanced AMD (wet or dry) in patients who have not been diagnosed with AMD, aged 55 and older and/or with a family history of AMD. The RetnaGene tests evaluate genotype and other known risk factors, giving a more complete assessment of a patient's individual risk for developing advanced AMD than with current phenotype-based standards.

Nicox Inc. and Sequenom Laboratories Enter into Exclusive Agreement in the Age-Related Macular Degeneration Field

Nicox Inc. and Sequenom Laboratories have entered into an exclusive agreement in the age-related macular degeneration field. As part of this agreement, Nicox has been granted the North American promotional rights to the Sequenom Laboratories RetnaGene AMD laboratory-developed test, for the evaluation of a patient's risk of AMD disease progression within two, five and ten years. The RetnaGene AMD test will be promoted by the same Nicox US sales force which recently launched Sjo, an advanced diagnostic panel for the early detection of Sjogren's Syndrome. Nicox expects to begin promoting the RetnaGene AMD test in the United States in the first half of 2014. Under the terms of the agreement, Sequenom Laboratories will grant Nicox exclusive rights to promote the RetnaGene AMD laboratory-developed test to eye care practitioners in North America (United States, Canada, Puerto Rico and Mexico) and co-exclusive rights towards specialized retina physicians. Sequenom Laboratories will provide the sample collection materials and will perform the testing in its CLIA-certified laboratory at an agreed price to Nicox. Further, Sequenom Laboratories will contribute existing commercial and clinical expertise, and marketing intelligence to expedite increased market demand and uptake within the general ophthalmology and optometry segments. Nicox will be responsible for all marketing and promotional activities, and will directly promote the RetnaGene AMD testing service to eye care practitioners.

Similar Private Companies By Industry

Company Name Region
Woodland Manor, Ltd. United States
Rhode Island Blood Center United States
DePaul Family Center United States
Medical Executive Coding & Auditing LLC United States
CellNetix Pathology & Laboratories, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact NicOx Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at